The University of Puerto Rico Medical Sciences Campus (UPR-MSC), has invested in infrastructure and fostered scientists to implement an impressive HIV/AIDS enterprise, covering the full spectrum of translational research. Mostly funded by NIH, the investigators from the MSC have notable achievements and have demonstrated capacity to sustain and expand research activities. One of our strength is the longstanding commitment of scientists and communities to jointly participate in HIV-related clinical, behavior and prevention trials. The investigators who are the leaders for this applicatio n: Integrated UPR Clinical Trials Unit (IUPR-CTU), have three decades of experience, have created research and care capacity, and are involved in mentoring the next generation of scientists (i.e. UPR Mentoring Institute for HIV and Mental Health: PI Zorrilla) and through specific network activities such as: IUPR CTU-PI/PD Carmen D. Zorrilla; ACTG-CRS-PI Jorge Santana and IMPAACT-CRS-PI Irma Febo. In order to address our specific aims, we will continue the operations of the IUPR-CTU which has been in existence in various forms for the past three decades. The IUPR-CTU is the evolution and integration of three separate and previously independent research units that were established with specific scientific agendas for to target populations which were key during the early years of the epidemic (pregnant women, infants, children and adolescents; and adults living with HIV), and that still need provision. The IUPR-CTU will continue to facilitate access to clinical and prevention clinical trials to a large number of participants of Hispanic ethnicity living in Puerto Rico. By participating in clinical trials of new drugs or combinations of drugs many patients have been exposed and received life-saving interventions prior to their commercial availability. In addition, the diversity of the patients recruited nationally has been expanded to represent the race, ethnicity and geographic location mostly affected by the epidemic. The IUPR-CTU will contribute to the research agenda of the NIH sponsored networks (ACTG, IMPAACT and HPTN) by sharing and aligning our infrastructure, our capacity and experience, our access to key populations, our community partnerships and support, and our commitment to investigators, staff and institutions with the goals of the networks,

Public Health Relevance

The Integrated UPR Clinical Trials Unit (IUPR-CTU) will continue to facilitate access to clinical and prevention clinical trials to a large number of participants of Hispanic ethnicity located in Puerto Rico, contributing with a broader perspective in scientific thinking and approaches.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Pouliot, Eileen M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Puerto Rico Med Sciences
Obstetrics & Gynecology
Schools of Medicine
San Juan
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Utay, Netanya S; Kitch, Douglas W; Yeh, Eunice et al. (2018) Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. J Infect Dis 217:1770-1781
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Taiwo, Babafemi O; Zheng, Lu; Stefanescu, Andrei et al. (2018) ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 66:1689-1697
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Gandhi, Monica; Gandhi, Rajesh T; Stefanescu, Andrei et al. (2018) Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis 218:234-238
Cranston, Ross D; Cespedes, Michelle S; Paczuski, Pawel et al. (2018) High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis 45:266-271
Iribarren, Sarah J; Ghazzawi, Alhasan; Sheinfil, Alan Z et al. (2018) Mixed-Method Evaluation of Social Media-Based Tools and Traditional Strategies to Recruit High-Risk and Hard-to-Reach Populations into an HIV Prevention Intervention Study. AIDS Behav 22:347-357
Carballo-Diéguez, Alex; Balán, Ivan C; Brown 3rd, William et al. (2017) High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One 12:e0181607

Showing the most recent 10 out of 108 publications